| Resilience in Alzheimer's disease: Impact of operationalization and methodological choices | Alzheimer's & dementia |  | | 2025 | 136 | 400 |
|
| Alterations in gamma frequency oscillations correlate with cortical tau deposition in Alzheimer’s disease | Neurobiology of aging | | | 2024 | 131 | 232 |
|
| Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease | Neurology | | | 2024 | 111 | 178 |
|
| Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic | Journal of neurology, neurosurgery and psychiatry | | | 2023 | 278 | 331 |
|
| Recruitment of pre-dementia participants : main enrollment barriers in a longitudinal amyloid-PET study | Alzheimer's research & therapy | | | 2023 | 87 | 30 |
|
| Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study | Alzheimer's & dementia | | | 2023 | 157 | 222 |
|
| Analysis of psychological symptoms following disclosure of amyloid-positron emission tomography imaging results to adults with subjective cognitive decline | JAMA network open | | | 2023 | 104 | 146 |
|
| Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients : The AMYPAD-DPMS Randomized Clinical Trial | JAMA neurology | | | 2023 | 81 | 111 |
|
| Dementia prevention in memory clinics : recommendations from the european task force for brain health services | The Lancet regional health. Europe | | | 2023 | 127 | 320 |
|
| The probabilistic model of Alzheimer disease: the amyloid hypothesis revised | Nature reviews. Neuroscience |  | | 2022 | 176 | 1 |
|
| Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe | Alzheimer's & dementia | | | 2022 | 366 | 552 |
|
| The amyloid imaging for the prevention of Alzheimer's disease consortium : A European collaboration with global impact | Frontiers in neurology | | | 2022 | 81 | 31 |
|
| The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey | Journal of Alzheimer's disease | | | 2022 | 103 | 370 |
|
| Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study | Magnetic resonance imaging | | | 2021 | 117 | 0 |
|
| Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6 | Alzheimer's research & therapy | | | 2021 | 193 | 442 |
|
| Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison | European Journal of Nuclear Medicine and Molecular Imaging | | | 2021 | 353 | 256 |
|
| Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design | Alzheimer's Research and Therapy | | | 2021 | 457 | 514 |
|
| Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 | Alzheimer's research & therapy | | | 2021 | 233 | 377 |
|
| Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services — part 2 of 6 | Alzheimer's research & therapy | | | 2021 | 175 | 415 |
|
| Protocols for cognitive enhancement. a user manual for brain health services — part 5 of 6 | Alzheimer's research & therapy | | | 2021 | 168 | 278 |
|
| Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives | European journal of nuclear medicine and molecular imaging | | | 2021 | 233 | 137 |
|
| Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services — part 6 of 6 | Alzheimer's research & therapy | | | 2021 | 138 | 179 |
|
| Dementia risk communication. A user manual for Brain Health Services — part 3 of 6 | Alzheimer's research & therapy | | | 2021 | 144 | 286 |
|
| Multitracer model for staging cortical amyloid deposition using PET imaging | Neurology | | | 2020 | 21 | 134 |
|
| Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease | European Journal of Nuclear Medicine and Molecular Imaging | | | 2020 | 422 | 6 |
|
| Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study | Alzheimer's & Dementia | | | 2020 | 510 | 180 |
|
| Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies | Alzheimer's & Dementia | | | 2020 | 276 | 2 |
|
| Applying the ATN scheme in a memory clinic population: The ABIDE project | Neurology | | | 2019 | 429 | 1 |
|
| Medial temporal lobe atrophy and posterior atrophy scales normative values | NeuroImage: Clinical | | | 2019 | 512 | 384 |
|
| Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset | Journal of Neurology | | | 2019 | 356 | 455 |
|
| Is a large-scale screening for Alzheimer's disease possible? yes, in a few years | The Journal of Prevention of Alzheimer's Disease | | | 2019 | 316 | 7 |
|
| Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia | European Journal of Nuclear Medicine and Molecular Imaging | | | 2018 | 480 | 0 |
|
| Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease | European Journal of Nuclear Medicine and Molecular Imaging | | | 2018 | 466 | 0 |
|
| Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia | European Journal of Nuclear Medicine and Molecular Imaging | | | 2018 | 445 | 0 |
|
| Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders | European Journal of Nuclear Medicine and Molecular Imaging | | | 2018 | 377 | 0 |
|
| Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation | Journal of Alzheimer's Disease | | | 2018 | 405 | 0 |
|
| Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia | European Journal of Nuclear Medicine and Molecular Imaging | | | 2018 | 513 | 290 |
|
| Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET | Alzheimer's & Dementia | | | 2018 | 460 | 0 |
|
| Clinical utility of FDG-PET for the clinical diagnosis in MCI | European Journal of Nuclear Medicine and Molecular Imaging | | | 2018 | 462 | 0 |
|
| Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease | European Journal of Nuclear Medicine and Molecular Imaging | | | 2018 | 465 | 0 |
|
| Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia | European Journal of Nuclear Medicine and Molecular Imaging | | | 2018 | 446 | 252 |
|
| AMYPAD Diagnostic and Patient Management Study: Rationale and design | Alzheimer's & Dementia | | | 2018 | 484 | 369 |
|
| Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic | Neurodegenerative Diseases | | | 2016 | 432 | 1 |
|
| Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study | JAMA neurology | | | 2016 | 494 | 2 |
|
| Brain atrophy in Alzheimer's Disease and aging | Ageing research reviews | | | 2016 | 753 | 7 |
|
